Show simple item record

dc.contributor.authorBerry, JMen_US
dc.contributor.authorHoward, PWen_US
dc.contributor.authorKelland, LRen_US
dc.contributor.authorThurston, DEen_US
dc.date.accessioned2018-09-18T10:35:40Z
dc.date.issued2002-05-20en_US
dc.identifier10en_US
dc.identifier.citationBIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 pp. 1413 - 1416en_US
dc.identifier.issn0960-894Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2761
dc.identifier.doi10.1016/S0960-894X(02)00150-6en_US
dc.description.abstractThe first example of an N10-protected. (e.g., Psec, 15) pyrrolo[2,1-c][1,4]benzodiazepine (PBD) analogue that retains significant cytotoxicity in a number of tumour cell lines is reported. This prototype could lead to a new generation of clinically useful N10-protceted PBD prodrugs. (C) 2002 Published by Elsevier Science Ltd.en_US
dc.format.extent1413 - 1416en_US
dc.titleSynthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrugen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/S0960-894X(02)00150-6en_US
rioxxterms.licenseref.startdate2002-05-20en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBIOORGANIC & MEDICINAL CHEMISTRY LETTERSen_US
pubs.notesarticle-number: PII S0960-894X(02)00150-6 unique-id: ISI:000175648800020en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.volume12en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorKelland, Lloyden_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record